125 related articles for article (PubMed ID: 19082437)
21. Enhancing cisplatin sensitivity in MCF-7 human breast cancer cells by down-regulation of Bcl-2 and cyclin D1.
Yde CW; Issinger OG
Int J Oncol; 2006 Dec; 29(6):1397-404. PubMed ID: 17088977
[TBL] [Abstract][Full Text] [Related]
22. Long non‑coding RNA AK001796 contributes to cisplatin resistance of non‑small cell lung cancer.
Liu B; Pan CF; Ma T; Wang J; Yao GL; Wei K; Chen YJ
Mol Med Rep; 2017 Oct; 16(4):4107-4112. PubMed ID: 29067469
[TBL] [Abstract][Full Text] [Related]
23. MiR-222 and miR-29a contribute to the drug-resistance of breast cancer cells.
Zhong S; Li W; Chen Z; Xu J; Zhao J
Gene; 2013 Nov; 531(1):8-14. PubMed ID: 23994196
[TBL] [Abstract][Full Text] [Related]
24. G1 arrest induction represents a critical determinant for cisplatin cytotoxicity in G1 checkpoint-retaining human cancers.
Un F
Anticancer Drugs; 2007 Apr; 18(4):411-7. PubMed ID: 17351393
[TBL] [Abstract][Full Text] [Related]
25. MDA-7/IL-24 regulates the miRNA processing enzyme DICER through downregulation of MITF.
Pradhan AK; Bhoopathi P; Talukdar S; Scheunemann D; Sarkar D; Cavenee WK; Das SK; Emdad L; Fisher PB
Proc Natl Acad Sci U S A; 2019 Mar; 116(12):5687-5692. PubMed ID: 30842276
[TBL] [Abstract][Full Text] [Related]
26. 3'-Phosphoadenosine 5'-phosphosulfate synthase 1 (PAPSS1) knockdown sensitizes non-small cell lung cancer cells to DNA damaging agents.
Leung AW; Dragowska WH; Ricaurte D; Kwok B; Mathew V; Roosendaal J; Ahluwalia A; Warburton C; Laskin JJ; Stirling PC; Qadir MA; Bally MB
Oncotarget; 2015 Jul; 6(19):17161-77. PubMed ID: 26220590
[TBL] [Abstract][Full Text] [Related]
27. Knockdown of OCT4 may sensitize NSCLC cells to cisplatin.
Liu X; Ma M; Duan X; Zhang H; Yang M
Clin Transl Oncol; 2017 May; 19(5):587-592. PubMed ID: 27832473
[TBL] [Abstract][Full Text] [Related]
28. Downregulation of Dicer enhances tumor cell proliferation and invasion.
Han L; Zhang A; Zhou X; Xu P; Wang GX; Pu PY; Kang CS
Int J Oncol; 2010 Aug; 37(2):299-305. PubMed ID: 20596657
[TBL] [Abstract][Full Text] [Related]
29. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine.
Xiang Y; Ma N; Wang D; Zhang Y; Zhou J; Wu G; Zhao R; Huang H; Wang X; Qiao Y; Li F; Han D; Wang L; Zhang G; Gao X
Oncogene; 2014 Jan; 33(3):378-86. PubMed ID: 23318422
[TBL] [Abstract][Full Text] [Related]
30. Dicer is down-regulated in clear cell renal cell carcinoma and in vitro Dicer knockdown enhances malignant phenotype transformation.
Ma X; Fan Y; Gao Y; Zhang Y; Huang Q; Ai Q; Ni D; Chen W; Zhang P; Song E; Wang B; Shi T; Zheng T; Zhang X
Urol Oncol; 2014 Jan; 32(1):46.e9-17. PubMed ID: 24094887
[TBL] [Abstract][Full Text] [Related]
31. Dicer-dependent miRNAs provide an endogenous restraint on cytotrophoblast proliferation.
Forbes K; Farrokhnia F; Aplin JD; Westwood M
Placenta; 2012 Jul; 33(7):581-5. PubMed ID: 22516645
[TBL] [Abstract][Full Text] [Related]
32. Dicer-1 regulates proliferative potential of Drosophila larval neural stem cells through bantam miRNA based down-regulation of the G1/S inhibitor Dacapo.
Banerjee A; Roy JK
Dev Biol; 2017 Mar; 423(1):57-65. PubMed ID: 28109717
[TBL] [Abstract][Full Text] [Related]
33. MiR-218 regulates cisplatin chemosensitivity in breast cancer by targeting BRCA1.
He X; Xiao X; Dong L; Wan N; Zhou Z; Deng H; Zhang X
Tumour Biol; 2015 Mar; 36(3):2065-75. PubMed ID: 25394901
[TBL] [Abstract][Full Text] [Related]
34. microRNA-18a, a member of the oncogenic miR-17-92 cluster, targets Dicer and suppresses cell proliferation in bladder cancer T24 cells.
Tao J; Wu D; Li P; Xu B; Lu Q; Zhang W
Mol Med Rep; 2012 Jan; 5(1):167-72. PubMed ID: 21935572
[TBL] [Abstract][Full Text] [Related]
35. Concordant and discordant regulation of target genes by miR-31 and its isoforms.
Chan YT; Lin YC; Lin RJ; Kuo HH; Thang WC; Chiu KP; Yu AL
PLoS One; 2013; 8(3):e58169. PubMed ID: 23472152
[TBL] [Abstract][Full Text] [Related]
36. Effect of 5-azacytidine on miRNA expression in human breast cancer cells with different sensitivity to cytostatics.
Chekhun VF; Borikun TV; Lukianova NY
Exp Oncol; 2016 Mar; 38(1):26-30. PubMed ID: 27031715
[TBL] [Abstract][Full Text] [Related]
37. Contributions of microRNA dysregulation to cisplatin resistance in adenocarcinoma cells.
Pouliot LM; Shen DW; Suzuki T; Hall MD; Gottesman MM
Exp Cell Res; 2013 Feb; 319(4):566-74. PubMed ID: 23137650
[TBL] [Abstract][Full Text] [Related]
38. The effect of combined miR-200c replacement and cisplatin on apoptosis induction and inhibition of gastric cancer cell line migration.
Ghasabi M; Majidi J; Mansoori B; Mohammadi A; Shomali N; Shirafkan N; Baghbani E; Kazemi T; Baradaran B
J Cell Physiol; 2019 Dec; 234(12):22581-22592. PubMed ID: 31111481
[TBL] [Abstract][Full Text] [Related]
39. MiR-31 regulates the cisplatin resistance by targeting Src in gallbladder cancer.
Li M; Chen W; Zhang H; Zhang Y; Ke F; Wu X; Zhang Y; Weng M; Liu Y; Gong W
Oncotarget; 2016 Dec; 7(50):83060-83070. PubMed ID: 27825112
[TBL] [Abstract][Full Text] [Related]
40. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.
Kovalchuk O; Filkowski J; Meservy J; Ilnytskyy Y; Tryndyak VP; Chekhun VF; Pogribny IP
Mol Cancer Ther; 2008 Jul; 7(7):2152-9. PubMed ID: 18645025
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
